Sagimet Biosciences Inc. Liabilities and Equity in USD from Q4 2022 to Q3 2025

Taxonomy & unit: us-gaap: USD
Description: Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.
Summary: Sagimet Biosciences Inc. quarterly Liabilities and Equity history and growth rate from Q4 2022 to Q3 2025.
Sagimet Biosciences Inc. Liabilities and Equity for the quarter ending September 30, 2025 was $128M, a 26.5% decline year-over-year.

Liabilities and Equity, Quarterly (USD)

Liabilities and Equity, YoY Quarterly Growth (%)

Sagimet Biosciences Inc. Quarterly Liabilities and Equity (USD)

Period	Value	YoY Chg	Change %	Date	Report	Filed
Q3 2025	$128M	-$46.4M	-26.5%	Sep 30, 2025	10-Q	2025-11-13
Q2 2025	$137M	-$51.6M	-27.3%	Jun 30, 2025	10-Q	2025-08-13
Q1 2025	$146M	-$48.4M	-24.9%	Mar 31, 2025	10-Q	2025-05-08
Q4 2024	$160M	+$63.5M	+65.7%	Dec 31, 2024	10-Q	2025-11-13
Q3 2024	$175M	+$71.9M	+69.8%	Sep 30, 2024	10-Q	2024-11-14
Q2 2024	$189M	+$168M	+779%	Jun 30, 2024	10-Q	2024-08-14
Q1 2024	$195M			Mar 31, 2024	10-Q	2024-05-15
Q4 2023	$96.7M	+$63.7M	+193%	Dec 31, 2023	10-K	2025-03-12
Q3 2023	$103M			Sep 30, 2023	10-Q	2023-11-13
Q2 2023	$21.5M			Jun 30, 2023	10-Q	2023-08-21
Q4 2022	$33M			Dec 31, 2022	10-K	2024-03-25

* An asterisk sign (*) next to the value indicates that the value is likely invalid.